Noval oral anticoagulants (NOACs) are non-vitamin K antagonists that include apixaban (pharmacology podcast), dabigatran, rivaroxaban, and edoxaban. NOACs are highly predictable and are less likely to interact with other medications, making them more favorable than warfarin. However, this does not guarantee their safety as it related to drug interactions.

With the help of a few other board-certified pharmacists, we’ve been creating board certification study materials since 2015. Having taken the BCPS and BCGP exam twice each (initial certification and recertification), I feel like we have a lot to offer. With that said our content is not perfect, but it gets closer every year. We’ve

In part 2 of our series on CDAI basics in Crohn’s disease, I wanted to cover moderate to severe Crohn’s disease and how treatment may look a little different. As a quick refresher, CDAI stands for Crohn’s Disease Activity Index and as you can imagine it is a scoring system that provides an assessment

The Crohn’s Disease Activity Index (CDAI) is just what it sounds like. It is an assessment tool designed to determine the severity of Crohn’s disease. Wait, isn’t this a diagnostic tool intended for diagnosticians? As a pharmacist, why do I need to know about it? The CDAI helps us determine the severity of Crohn’s disease

I am going to outline a common case of escalating dosages of levothyroxine. I beg you to ALWAYS look for binding interactions with levothyroxine when you see dose increases!